1. XERMELO prescribing information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February 2017.2. Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Oncologist. 2016;21:701-707.
You may report an adverse event related to TerSera Therapeutics products by calling 1-844-334-4035 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit MedWatch or call 1-800-FDA-1088.
Xermelo® is a registered trademark of TerSera Therapeutics LLC or its affiliates.
© 2020 TerSera Therapeutics LLC. All rights reserved.
XER-P-0040 V4 (10/2022)
XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Please see Full Prescribing Information.